CSL Limited

ARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial Results

Retrieved on: 
Thursday, May 9, 2024
CSL Limited, FDA, Investment, NDA, Research, MAA, CHMP, ASX, Trial of the century, ARS, PDUFA, European Medicines Agency, Patient, Adrenaline, Anaphylaxis, CSL, EMA, Caregiver, Committee, Allergy, Upper respiratory tract infection, CRL, Clinical trial, SAN, Journal, G&A

SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today reported business updates and financial results for the first quarter of 2024.

Key Points: 
  • Assuming approval on or before the anticipated PDUFA date, ARS Pharma anticipates launching neffy in the U.S. in the second half of 2024.
  • Following local regulatory approval of neffy, ARS Pharma will be responsible for supplying finished product to CSL Seqirus at a transfer price paid to ARS Pharma.
  • G&A expenses decreased from 2023 to 2024 primarily due to a pause in pre-commercial launch activities related to neffy.
  • Net Loss: Net loss was $10.3 million for the quarter ended March 31, 2024, compared to $15.0 million for the quarter ended March 31, 2023.

COVID-19 Monthly Newsletter Service - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 14, 2024
Biotechnology, Pharmaceutical, Publishing, Health, FDA, COVID-19, Communications, Clinical Trials, MHLW, CSL, Abivax, AstraZeneca, Partnership, University, Ageing, EUL, Arcturus Therapeutics, UNICEF, Bharat Biotech, Ministry of Health, XBB, Messenger, Laboratory, World Health Organization, OTC, Therapy, Johnson & Johnson, Vaccination, Rapid antigen test, Phase II, WHO, CSL Limited, Ministry, Vaccine, Marketing, Fulcrum, UN, Pharmaceutical industry

The "COVID-19 Monthly Snapshot" newsletter has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "COVID-19 Monthly Snapshot" newsletter has been added to ResearchAndMarkets.com's offering.
  • In November 2023, 64 investigational drugs were active in Phase 3 of clinical development.
  • Globally, the overall confirmed cases of COVID-19 reached more than 772 million as of November 22, 2023.
  • Fifty-eight COVID-19 vaccines were evaluated in Phase 3, 40 in Phase 2, 84 in Phase 1, and 199 in pre-clinical stages.

Half year reported NPATA US$2 billion¹,² Up 13% at constant currency³

Retrieved on: 
Tuesday, February 13, 2024
Acquisition, Warfarin, CSL Behring, Depreciation, Research, Ministry, Messenger, CIDP, Marketing, CSL, Growth, Plasmapheresis, Primary immunodeficiency, Von Willebrand disease, Antibody, S&M, Immunodeficiency, ASX, Income tax, Haemophilia, HAE, Ministry of Health, CSL Vifor, Hereditary angioedema, Plasma, COVID, Patient, Webcast, Phase, Diagnosis, G&A, CC3, Pressure, CSL Limited, Vaccine

MELBOURNE, Australia, Feb. 13, 2024 /PRNewswire/ -- CSL Limited (ASX:CSL; USOTC:CSLLY) today announces a reported net profit after tax of $1.90 billion1 for the 6 months ended 31 December 2023, up 20% on a constant currency basis3. Underlying profit (NPATA) was $2.02 billion1,2, up 13% on a constant currency basis to $2.06 billion1,2,3.

Key Points: 
  • Underlying profit (NPATA) was $2.02 billion1,2, up 13% on a constant currency basis to $2.06 billion1,2,3.
  • Immunoglobulin (Ig) product sales of $2,757 million, increased 23%3 with strong growth recorded across all geographies driven by global plasma supply and patient demand.
  • HIZENTRA® (Immune Globulin Subcutaneous (Human), 20% Liquid) sales were up 18%3 driven by  patient diagnosis rates.
  • However, due to the seasonality of this business we anticipate it to post a loss in the second half of the fiscal year.

Half year reported NPATA US$2 billion¹,² Up 13% at constant currency³

Retrieved on: 
Tuesday, February 13, 2024
Acquisition, Warfarin, CSL Behring, Depreciation, Research, Ministry, Messenger, CIDP, Marketing, CSL, Growth, Plasmapheresis, Primary immunodeficiency, Von Willebrand disease, Antibody, S&M, Immunodeficiency, ASX, Income tax, Haemophilia, HAE, Ministry of Health, CSL Vifor, Hereditary angioedema, Plasma, COVID, Patient, Webcast, Phase, Diagnosis, G&A, CC3, Pressure, CSL Limited, Vaccine

MELBOURNE, Australia, Feb. 13, 2024 /PRNewswire/ -- CSL Limited (ASX:CSL; USOTC:CSLLY) today announces a reported net profit after tax of $1.90 billion1 for the 6 months ended 31 December 2023, up 20% on a constant currency basis3. Underlying profit (NPATA) was $2.02 billion1,2, up 13% on a constant currency basis to $2.06 billion1,2,3.

Key Points: 
  • Underlying profit (NPATA) was $2.02 billion1,2, up 13% on a constant currency basis to $2.06 billion1,2,3.
  • Immunoglobulin (Ig) product sales of $2,757 million, increased 23%3 with strong growth recorded across all geographies driven by global plasma supply and patient demand.
  • HIZENTRA® (Immune Globulin Subcutaneous (Human), 20% Liquid) sales were up 18%3 driven by  patient diagnosis rates.
  • However, due to the seasonality of this business we anticipate it to post a loss in the second half of the fiscal year.

Enterprise Connect 2024 Expands Conference Program, Adds RingCentral CEO Keynote

Retrieved on: 
Wednesday, November 15, 2023
Other Professional Services, Data Analytics, Blogging, Public Relations, Investor Relations, Marketing, Consulting, Communications, Professional Services, Accenture, Delta Air Lines, Learning, Cargill, Consultant, Cisco, Lehman Brothers, Zoom, Hewlett Packard Enterprise, CSL Limited, EVP, RingCentral, Strategy, Software, Exhibition, EY, Microsoft, Sprint Corporation, Management, Experian, Hong Kong

Enterprise Connect , the leading conference and exhibition for enterprise communications and customer experience, today announces Tarek Robbiati, Chief Executive Officer of RingCentral will deliver a keynote presentation.

Key Points: 
  • Enterprise Connect , the leading conference and exhibition for enterprise communications and customer experience, today announces Tarek Robbiati, Chief Executive Officer of RingCentral will deliver a keynote presentation.
  • Enterprise Connect takes place March 25-28, 2024 at the Gaylord Palms in Orlando, FL.
  • For more than 30 years, Enterprise Connect has brought corporate IT decision makers together with industry vendors, analysts, consultants, and channel partners to focus on the issues central to enterprise communications and customer experience.
  • Over three days of a sponsor expo and four days of the conference program, Enterprise Connect showcases the latest systems, software, services and applications, and helps attendees understand the industry.

Industry Veteran Abbas Hussain Appointed as Chair of Asceneuron

Retrieved on: 
Monday, December 18, 2023
SAN, Chair, Teva Pharmaceuticals, Abingworth (company), Patient, Adviser, Sofinnova, Spondyloarthropathy, Medicinal chemistry, Capital, CSL Limited, Stanford University, Eli Lilly, Pamlab, Conference, CSL Vifor, Non-executive director, Growth, GSK plc, OGA, Cochlear Limited, Pharmaceutical industry, Science, Immunocore

Abbas Hussain has over 35 years of experience in the healthcare industry, building and growing businesses across the globe.

Key Points: 
  • Abbas Hussain has over 35 years of experience in the healthcare industry, building and growing businesses across the globe.
  • Abbas Hussain, Chair of the Board of Directors of Asceneuron, remarked: "There have been tremendous advances in the treatment of neurodegenerative disorders which impact millions of people globally every year.
  • Abbas currently holds various Non-Executive Director and Advisor roles at Alfasigma SpA, 4Bio Capital, C-Bridge Capital and GLG Institute.
  • In addition, Abbas also provides expert advisory services to private equity and venture capital firms focused on the healthcare sector.

Industry Veteran Abbas Hussain Appointed as Chair of Asceneuron

Retrieved on: 
Monday, December 18, 2023
SAN, Chair, Teva Pharmaceuticals, Abingworth (company), Patient, Adviser, Sofinnova, Spondyloarthropathy, Medicinal chemistry, Capital, CSL Limited, Stanford University, Eli Lilly, Pamlab, Conference, CSL Vifor, Non-executive director, Growth, GSK plc, OGA, Cochlear Limited, Pharmaceutical industry, Science, Immunocore

Abbas Hussain has over 35 years of experience in the healthcare industry, building and growing businesses across the globe.

Key Points: 
  • Abbas Hussain has over 35 years of experience in the healthcare industry, building and growing businesses across the globe.
  • Abbas Hussain, Chair of the Board of Directors of Asceneuron, remarked: "There have been tremendous advances in the treatment of neurodegenerative disorders which impact millions of people globally every year.
  • Abbas currently holds various Non-Executive Director and Advisor roles at Alfasigma SpA, 4Bio Capital, C-Bridge Capital and GLG Institute.
  • In addition, Abbas also provides expert advisory services to private equity and venture capital firms focused on the healthcare sector.

American Lung Association Urges Everyone to Get Vaccinated During National Influenza Vaccination Week

Retrieved on: 
Monday, December 4, 2023
COPD, American Lung Association, Black, Alaska Natives, Ageing, Risk, American Indians, Vaccination, CSL Limited, Season, Health, COVID-19, Friends, CDC, Chronic obstructive pulmonary disease, Family, Diabetes, Asthma, Hospital, Public, Chronic lung disease, Vaccine, Poultry farming

To increase flu vaccination rates, safeguard public health and save lives, the American Lung Association announces its 2023 flu campaign during National Influenza Vaccination Week (December 4 – 8).

Key Points: 
  • To increase flu vaccination rates, safeguard public health and save lives, the American Lung Association announces its 2023 flu campaign during National Influenza Vaccination Week (December 4 – 8).
  • "Protecting yourself through vaccination not only protects your health but helps protect those who are most vulnerable.
  • The 2022-23 flu season revealed some alarming trends :
    37% of flu related hospitalizations were among adults with chronic lung disease.
  • The American Lung Association remains dedicated to advancing respiratory health and well-being across the nation.

Axsome Therapeutics Appoints Dr. Sue Mahony to its Board of Directors

Retrieved on: 
Wednesday, October 11, 2023
Aston, Eli Lilly and Company, Acquisition, Doctor of Philosophy, Amgen, Drug development, Business, London School of Management Education, Central nervous system, MD, Organization, University, Mahony, Patient, Chordoma, Therapy, CSL Limited, Schering-Plough, Marketing, Master of Business Administration, Business administration, CNS, CSL Vifor, Horizon Therapeutics, London School of Business and Finance, Pharmaceutical industry, Management, Pharmacy, Philosophy, Lilly, Science

Dr. Mahony most recently served on the board of directors of Horizon Therapeutics from 2019 until its acquisition by Amgen in October 2023.

Key Points: 
  • Dr. Mahony most recently served on the board of directors of Horizon Therapeutics from 2019 until its acquisition by Amgen in October 2023.
  • “We are pleased to welcome Dr. Mahony, who has extensive leadership experience in global drug development and commercialization, to our board of directors,” said Herriot Tabuteau, MD, Chief Executive Officer of Axsome.
  • Dr. Mahony served on the board of directors of Vifor Pharma from 2019 until its acquisition by CSL Limited in 2022.
  • Dr. Mahony also serves on the board of directors of the Chordoma Foundation, a nonprofit dedicated to improving the lives of people affected by chordoma.

Asceneuron Welcomes Barbara Angehrn Pavik as New CEO as It Gears Up for Next Phase of Growth

Retrieved on: 
Friday, October 6, 2023
Biotechnology, Mental Health, Other Health, Health, Clinical Trials, Acquisition, Amgen, CSL Vifor, CSL Limited, Growth, Onyx, Management, EU, Exelixis

Dirk Beher, co-founder of Asceneuron, its original Chief Scientific Officer, and CEO since 2014, will transition to the key role of Chief Scientific Advisor.

Key Points: 
  • Dirk Beher, co-founder of Asceneuron, its original Chief Scientific Officer, and CEO since 2014, will transition to the key role of Chief Scientific Advisor.
  • "Dirk's leadership and unwavering dedication has been a cornerstone of Asceneuron, enabling the company to become a true pioneer in our field," said Peter Van Vlasselaer, the Board Chair.
  • Most recently, as the Chief Business Officer at Vifor, Angehrn Pavik played a key role in the company's acquisition by CSL Limited.
  • "I am deeply honored to be joining the Asceneuron team at this transformative juncture," Angehrn Pavik said.